Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23560055 | 1.00 | HRH3 (0.42) | HRH3PIK3CDKDM4EALDH1A1TDP1 | |
| SCHEMBL23695835 | 1.00 | HRH3 (0.42) | HRH3PIK3CDKDM4EALDH1A1TDP1 | |
| SCHEMBL25122854 | 0.86 | HRH3 (0.36) | HRH3SMN1; SMN2 | |
| SCHEMBL22856410 | 0.86 | HRH3 (0.36) | HRH3SMN1; SMN2 | |
| SCHEMBL23560058 | 0.83 | HRH3 (0.38) | HRH3SIGMAR1SMN1; SMN2 | |
| SCHEMBL14706853 | 0.81 | HRH3 (0.46) | HRH3PIK3CDKDM4EALDH1A1TDP1 | |
| SCHEMBL23560035 | 0.77 | HRH3 (0.49) | HRH3PIK3CDKDM4EALDH1A1TDP1 | |
| SCHEMBL22837708 | 0.76 | HRH3 (0.43) | HRH3PIK3CDKDM4EALDH1A1TDP1 | |
| SCHEMBL6923874 | 0.75 | HRH3 (0.47) | HRH3PIK3CDKDM4EALDH1A1TDP1 | |
| SCHEMBL22856352 | 0.74 | HRH3 (0.41) | HRH3PIK3CDCYP2D6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4393922-A1 | IRAK4 DEGRADATION AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| EP-4328219-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| EP-4194457-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Leadingtac Pharmaceutical Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
| WO-2023081759-A1 | BIFUNCTIONAL PI3K-ALPHA INHIBITORS AND USES THEREOF | RELAY THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | HRH3 3763/4885PIK3CD 653/4885KDM4E 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.